JP2023515573A5 - - Google Patents

Info

Publication number
JP2023515573A5
JP2023515573A5 JP2022551284A JP2022551284A JP2023515573A5 JP 2023515573 A5 JP2023515573 A5 JP 2023515573A5 JP 2022551284 A JP2022551284 A JP 2022551284A JP 2022551284 A JP2022551284 A JP 2022551284A JP 2023515573 A5 JP2023515573 A5 JP 2023515573A5
Authority
JP
Japan
Prior art keywords
item
antigen
activatable
shielded
binding protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022551284A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023515573A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/019331 external-priority patent/WO2021173612A1/en
Publication of JP2023515573A publication Critical patent/JP2023515573A/ja
Publication of JP2023515573A5 publication Critical patent/JP2023515573A5/ja
Pending legal-status Critical Current

Links

JP2022551284A 2020-02-26 2021-02-24 普遍的な遮蔽性部分を有する活性化可能な抗原結合性タンパク質 Pending JP2023515573A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062981782P 2020-02-26 2020-02-26
US62/981,782 2020-02-26
PCT/US2021/019331 WO2021173612A1 (en) 2020-02-26 2021-02-24 Activatable antigen binding proteins with universal masking moieties

Publications (2)

Publication Number Publication Date
JP2023515573A JP2023515573A (ja) 2023-04-13
JP2023515573A5 true JP2023515573A5 (cg-RX-API-DMAC7.html) 2024-03-06

Family

ID=75108796

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022551284A Pending JP2023515573A (ja) 2020-02-26 2021-02-24 普遍的な遮蔽性部分を有する活性化可能な抗原結合性タンパク質

Country Status (6)

Country Link
US (1) US20230183377A1 (cg-RX-API-DMAC7.html)
EP (1) EP4110817A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023515573A (cg-RX-API-DMAC7.html)
CN (1) CN115485300A (cg-RX-API-DMAC7.html)
CA (1) CA3168986A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021173612A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024532409A (ja) * 2021-08-23 2024-09-05 コンセプト トゥー メディシン バイオテック カンパニー, リミテッド 定常ドメインを有する抗体プロドラッグ
JP7767613B2 (ja) 2021-11-15 2025-11-11 システィミューン,インコーポレイテッド 二重特異性抗体-カンプトテシン薬物複合体及びその製薬的使用
JPWO2024071043A1 (cg-RX-API-DMAC7.html) * 2022-09-30 2024-04-04
EP4761818A1 (en) * 2023-08-18 2026-06-24 F. Hoffmann-La Roche AG Protease activatable fc domain binding molecules
CN119234000B (zh) * 2023-09-25 2026-04-17 深圳湾实验室 可激活穿膜构建体和降解子
CN122422352A (zh) * 2023-12-11 2026-07-17 豪夫迈·罗氏有限公司 蛋白酶可活化的Fc结构域结合分子
WO2025240659A2 (en) * 2024-05-14 2025-11-20 Cytomx Therapeutics, Inc. Activatable constructs, compositions and methods
CN119776391A (zh) * 2024-12-23 2025-04-08 四川康德赛医疗科技有限公司 编码抗体-抗原融合蛋白的mRNA或mRNA-LNP复合物及其应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US251202A (en) 1881-12-20 Farm-gate
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
JP3051145B2 (ja) 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化b−b10
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
GB0025144D0 (en) 2000-10-13 2000-11-29 Medical Res Council Concatenated nucleic acid sequences
US20040202995A1 (en) 2003-04-09 2004-10-14 Domantis Nucleic acids, proteins, and screening methods
WO2010127284A2 (en) 2009-05-01 2010-11-04 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
CA2805442C (en) 2010-07-21 2020-05-12 Sangamo Biosciences, Inc. Methods and compositions for modification of an hla locus
CN104640572B (zh) 2012-05-15 2018-04-27 索伦托医疗有限公司 药物偶联物,偶联方法,及其用途
ES2728782T3 (es) 2012-05-25 2019-10-28 Univ California Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN
WO2014059173A2 (en) 2012-10-10 2014-04-17 Sangamo Biosciences, Inc. T cell modifying compounds and uses thereof
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
WO2016014794A1 (en) 2014-07-25 2016-01-28 Sangamo Biosciences, Inc. Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells
US9616090B2 (en) 2014-07-30 2017-04-11 Sangamo Biosciences, Inc. Gene correction of SCID-related genes in hematopoietic stem and progenitor cells
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
US9949700B2 (en) 2015-07-22 2018-04-24 Inneroptic Technology, Inc. Medical device approaches
JP2019532644A (ja) 2016-09-30 2019-11-14 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Rna誘導型核酸修飾酵素及びその使用方法
WO2018213335A1 (en) * 2017-05-16 2018-11-22 Scalmibio, Inc. Activatable antibodies and methods of use thereof
AR113862A1 (es) * 2017-12-01 2020-06-17 Seattle Genetics Inc Anticuerpos anti-cd47 y sus usos para tratar cáncer
US20200385440A1 (en) * 2017-12-07 2020-12-10 Janux Therapeutics, Inc. Modified bispecific t cell receptors

Similar Documents

Publication Publication Date Title
JP7638531B2 (ja) Her3に対する抗原結合タンパク質
AU2018304711A1 (en) Methods of qualitatively and/or quantitatively analyzing properties of activatable antibodies and uses thereof
CN114591433A (zh) 抗pd-1抗体、可活化抗pd-1抗体及其使用方法
CN104271602A (zh) 双特异性抗体
US12391770B2 (en) Compositions and methods comprising antibodies that bind to covalent peptide conjugates
TW202200619A (zh) 引導及導航控制(gnc)抗體樣蛋白質及製造與使用其之方法
CN113646328A (zh) 一种免疫细胞因子及其制备与用途
CN119233993A (zh) 用于靶向t细胞活化的cd28双特异性抗体
CA3052291A1 (en) Anti-kir3dl1 antibodies
WO2024193635A1 (en) Sirp variants and uses thereof
CN118974100A (zh) 针对人tim-3和人cd39的双特异性抗体和其用途
JP2025513930A5 (cg-RX-API-DMAC7.html)
CN115894702A (zh) 一种b7h3/pdl1双特异性抗体及其药物组合物及应用
JP2023533857A (ja) 抗klk2抗体に対する抗イディオタイプ抗体
US20220175945A1 (en) Antibodies and enonomers
CN107109423A (zh) 用于生产双特异性抗体的细胞的制备和挑选
US20230287082A1 (en) Nkp30 binders
Claus et al. Article Not peer-reviewed version
HK40129137A (en) Guidance and navigation control (gnc) antibody-like proteins and methods of making and using thereof
HK40129779A (zh) 制导和导航控制(gnc)抗体样蛋白及其制备和使用方法
CN117615782A (zh) 包含结合至共价肽偶联物的抗体的组合物和方法
CN118725130A (zh) 抗ctla-4/抗tigit双特异性抗体及其应用
CN116507634A (zh) Nkp30结合剂
CN119234000A (zh) 可激活穿膜构建体和降解子